Compare Cassava Sciences Inc (FLNA) vs Schwab US Large Cap Growth ETF (SCHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Schwab US Large Cap Growth ETF — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while Schwab US Large Cap Growth ETF trades at $34.84. The key difference: Schwab US Large Cap Growth ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | SCHG | |
|---|---|---|
Market Cap | $53.14M | — |
Sector | Health | Sector/Thematic |
52-Week High | $4.64 | $35.30 |
52-Week Low | $1.09 | $28.10 |
Enterprise Value | -$33.43M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.
The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.
SCHG trades at $34.75, up 0.49% with a bullish technical signal from moving averages but mixed oscillators. The ETF provides concentrated exposure to large-cap growth stocks, particularly in technology and AI sectors, with top holdings including Nvidia, Apple, and Microsoft. Recent news highlights strong institutional interest and positioning for AI-driven growth, though concerns exist about high concentration risk and premium valuations.
Outlook remains positive given AI investment tailwinds and strong institutional flows, but investors face risks from sector concentration and potential valuation compression if growth expectations disappoint. The ETF's low-cost structure and focus on innovation leaders offer long-term growth potential despite near-term volatility concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Schwab US Large Cap Growth ETF
SCHG is an ETF that seeks to track the total return of the Dow Jones U.S. Large-Cap Growth Total Stock Market Index. The fund provides low-cost exposure to a diversified portfolio of large-capitalization U.S. companies that are classified as growth stocks based on factors such as sales, earnings, and book value growth rates. SCHG is often used by investors seeking long-term capital appreciation from market-leading companies with above-average growth potential.
Read more on SCHG →
